Selvita S.A.
↗Krakow, Poland
Selvita is one of the largest preclinical contract research organizations (CRO) in Europe, providing integrated drug discovery and development services to the pharmaceutical and biotechnology industries. Founded in 2007 and headquartered in Krakow, Poland, the company operates globally with research sites across Poland and Croatia, and business offices in the U.S. and U.K. Selvita specializes in bridging the gap between early-stage research and clinical development.
In 2019, Selvita underwent a corporate split, spinning off its proprietary drug discovery business into Ryvu Therapeutics to focus exclusively on high-quality service provision. Since then, Selvita has aggressively expanded its capabilities through organic growth and strategic acquisitions, such as Fidelta in 2021 and PozLab in 2024, positioning itself as a comprehensive partner for small molecules, antibodies, and advanced modalities like protein degraders and ADCs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$95M-$127M
Founded:2007
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$20.6M (Secondary Offering 2020)
Investors:Institutional investors on WSE, Boguslaw Sieczkowski (Co-founder)
STOCK
Exchange:Warsaw Stock Exchange (WSE)
Ticker:SLV
Market Cap:$227M
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical (Service-based)
Modalities:Small molecule, Antibodies, Protein degraders, ADC, Oligonucleotides
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Fidelta d.o.o. (Croatia), PozLab sp. z o.o. (Poland), Ardigen S.A. (Bioinformatics subsidiary)
Key Partnerships:Galapagos (Long-term service agreement), University of Oxford (Parkinson's disease collaboration), Merck (R&D partnership), Menarini Group (Legacy licensing)
COMPETITION
Position:Leader
Competitors:Evotec, Charles River Laboratories, Sygnature Discovery, Pharmaron, WuXi AppTec, Eurofins
LEADERSHIP
Key Executives:
Boguslaw Sieczkowski - CEO & Co-founder
Paul Overton - Chief Commercial Officer
Milosz Gruca - Global Head of Drug Development
Scientific Founders:Pawel Przewiezlikowski, Boguslaw Sieczkowski
Board Members:Piotr Romanowski (Chairman), Jacek Osowski
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Selvita S.A.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.